Company Product Description Indication Status
Phase I
Acepodia Inc., of San Francisco and Taipei, Taiwan ACE-1702  Allogeneic natural killer cell therapy targeting HER2 HER2-expressing solid tumors  First of up to 24 patients treated
Aligos Therapeutics Inc., of South San Francisco ALG-010133 S-antigen transport-inhibiting oligonucleotide polymer Chronic hepatitis B Dosed first subject in phase Ia/b study testing the safety, pharmacokinetics and antiviral activity of the drug in healthy volunteers and virologically suppressed patients with chronic hepatitis B
Arrowhead Pharmaceuticals Inc., of Pasadena, Calif. ARO-HIF2 RNAi targeting HIF-2alpha Clear cell renal cell carcinoma Treated first patient in the phase Ib AROHIF21001 study designed to determine the recommended phase II dose; pharmacokinetics, response rate and expression of HIF genes will also be measured
Deciphera Pharmaceuticals LLC, of Waltham, Mass. Qinlock (ripretinib) Switch-control tyrosine kinase inhibitor Second-line through fourth-line-plus gastrointestinal stromal tumor Data published in Journal of Clinical Oncology showed an objective response rate of 19.4%, 14.3% and 7.2% for second-line, third-line and fourth or greater lines, respectively
Immatics NV, of Tuebingen, Germany IMA-202 Targets peptides derived from melanoma-associated antigen 1 Solid tumors expressing melanoma-associated antigen 1 Treated first patient in the IMA202-101 trial
Intravacc, of Bilthoven, the Netherlands, Respiratory syncytial virus vaccine Live attenuated respiratory syncytial virus vaccine without the G protein Respiratory syncytial virus infection prophylaxis Data published in Vaccine showed side effects of the vaccine were mild and comparable to placebo; antibody levels were comparable before and after immunization and between vaccine and placebo groups due to a high background immunity
Maxcyte Inc., of Gaithersburg, Md. MCY-M11 Anti-mesothelin CAR-PBMC cell therapy Relapsed/refractory ovarian cancer and malignant peritoneal mesothelioma Added a parallel cohort of patients to receive escalating doses of intraperitoneal delivery of MCY-M11 with a preconditioning regimen of cyclophosphamide; added 2 additional research sites
Organicell Regenerative Medicine Inc., of Miami Zofin Perinatal-derived microRNAs COVID-19 Plans to start a 20-patient phase I/II study within the next 2 weeks
Poseida Therapeutics Inc., of San Diego P-PSMA-101  CAR T therapy targeting PSMA Metastatic castrate-resistant prostate cancer Study put on clinical hold following patient death
Telix Pharmaceuticals Japan K.K., of Tokyo, a unit of Telix Pharmaceuticals Ltd. TLX250-CDx (89Zr-girentuximab) Diagnostic imaging product Clear cell renal cell cancer First patient dosed in the phase I/II ZIRDAC-JP study in Japan
Ultimovacs ASA, of Oslo, Norway UV-1 Peptide vaccine based on antigen from telomerase Metastatic malignant melanoma Started patient enrollment in the study testing UV-1 with Keytruda (pembrolizumab, Merck & Co. Inc.)
Phase II
Clovis Oncology Inc., of Boulder, Colo. Rubraca (rucaparib) Inhibitor of PARP1, PARP2 and PARP3  Metastatic castration-resistant prostate cancer harboring BRCA1/2 mutations Data published in the Journal of Clinical Oncology showed the drug produced an objective response rate of 43.5% confirmed by independent radiology review; PSA response rate was 54.8%
Follicum AB, of Lund, Sweden FOL-005 Short version of osteopontin Hair loss More than 50% of the 200 patients have been enrolled
Immunicum AB, of Stockholm Ilixadencel Off-the-shelf cell-based cancer immunotherapy Kidney cancer  Survival data from Mereca trial showed median overall survival (OS) was reached at 25 months in control group treated with sunitinib, while final median OS value in ilixadencel group has not yet been reached, indicating survival benefit in co-primary endpoint
Immutep Ltd., of Sydney Eftilagimod alpha (IMP-321) HLA class II antigen stimulator  Second-line head and neck squamous cell carcinoma or first- and second-line non-small-cell lung cancer Completed enrollment of 23 patients with second-line NSCLC in stage 1 part B in the TACTI-002 study; data monitoring committee will review data after all patients have undergone at least 1 post-treatment tumor imaging to decide about opening stage 2 part B; enrollment is ongoing for stage 2 part C in second-line HNSCC
The University of Texas MD Anderson Cancer Center, Glaxosmithkline plc, of London, and Novartis AG, of Basel, Switzerland Dabrafenib and trametinib BRAF inhibitor and a MEK inhibitor Cholangiocarcinoma with a BRAF V600E mutation Data from the 43-patient cohort published in Lancet Oncology showed the combination produced a 51% overall response rate
Phase III
Vanda Pharmaceuticals Inc., of Washington Tradipitant  Neurokinin-1 receptor antagonist  COVID-19 pneumonia Interim analysis of the Odyssey study showed tradipitant accelerated clinical improvement by day 7 (p=0.0375); median time to improvement was 10 days for tradipitant and 28 days for placebo (p=0.2254)

Notes

For more information about individual companies and/or products, see Cortellis.